Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HEPA 
Hepion Pharmaceuticals Inc (HEPA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: HEPA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.99M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta 1.55 | 52 Weeks Range 0.04 - 56.00 | Updated Date 06/30/2025 |
52 Weeks Range 0.04 - 56.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -81.37 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -86.54% | Return on Equity (TTM) -288.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1594549 | Price to Sales(TTM) - |
Enterprise Value -1594549 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.1 | Shares Outstanding 10976300 | Shares Floating 10135932 |
Shares Outstanding 10976300 | Shares Floating 10135932 | ||
Percent Insiders 0.19 | Percent Institutions 8.95 |
Analyst Ratings
Rating 1 | Target Price 30 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Hepion Pharmaceuticals Inc
Company Overview
History and Background
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel therapeutics targeting liver disease. Founded in 2014, it has focused on developing compounds to treat non-alcoholic steatohepatitis (NASH) and other chronic liver diseases.
Core Business Areas
- Drug Development: Focuses on research and development of novel therapies, primarily Rencofilstat, for the treatment of NASH and other liver diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates.
- Intellectual Property: Manages and protects its intellectual property portfolio related to its drug candidates.
Leadership and Structure
Robert Foster is the current CEO. The company has a board of directors overseeing strategic direction. Hepion operates with functional departments for R&D, clinical operations, and corporate affairs.
Top Products and Market Share
Key Offerings
- Rencofilstat: Hepion's lead drug candidate, Rencofilstat, is an oral CRN2 inhibitor being developed for NASH. It is currently undergoing clinical trials. Market share data is not yet available as the drug is not yet commercialized. Competitors include Madrigal Pharmaceuticals (resmetirom) and Viking Therapeutics (VK2809).
Market Dynamics
Industry Overview
The liver disease therapeutics market, particularly for NASH, is a large and growing market. There is a significant unmet need for effective treatments.
Positioning
Hepion is positioned as an innovator in liver disease therapeutics, specifically targeting CRN2. Their competitive advantage lies in their novel mechanism of action.
Total Addressable Market (TAM)
The NASH market is projected to reach tens of billions of dollars. Hepion, with Rencofilstat, aims to capture a portion of this market. Various reports give estimates in the 20-50 billion dollar range over the next decade, depending on variables. Hepion is positioning itself to be a major player in the NASH market.
Upturn SWOT Analysis
Strengths
- Novel CRN2 inhibitor mechanism
- Potential for disease modification in NASH
- Experienced management team
- Proprietary intellectual property
Weaknesses
- Single lead drug candidate (Rencofilstat)
- High cash burn rate
- Dependence on clinical trial success
- Lack of commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other liver diseases
- Positive clinical trial results
- Regulatory approval of Rencofilstat
Threats
- Clinical trial failures
- Competition from other NASH therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
Competitive Landscape
Hepion's competitive advantage lies in their unique CRN2 inhibitor mechanism. However, they face competition from larger companies with more advanced NASH programs.
Growth Trajectory and Initiatives
Historical Growth: Growth has been focused on advancing Rencofilstat through clinical development.
Future Projections: Future growth is highly dependent on the successful development and commercialization of Rencofilstat. Analyst estimates vary depending on perceived probability of success.
Recent Initiatives: Recent initiatives focus on advancing clinical trials of Rencofilstat and seeking potential partnerships.
Summary
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on novel liver disease treatments, particularly NASH. Their lead candidate, Rencofilstat, shows promise but is still in clinical development. The company is highly dependent on the success of clinical trials and faces competition from larger players. Financial stability and strategic partnerships will be critical for Hepion's future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hepion Pharmaceuticals' SEC filings
- ClinicalTrials.gov
- Analyst reports (e.g., from brokerage firms)
- Company press releases
- Third party Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data for competitors is based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hepion Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Morristown, NJ, United States | ||
IPO Launch date 2014-02-11 | Interim CEO & Director Dr. Kaouthar Lbiati M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://hepionpharma.com |
Full time employees - | Website https://hepionpharma.com | ||
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.